Mga Batayang Estadistika
| LEI | 5493005KN31IIY2XSQ42 |
| CIK | 876378 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Asensus Surgical, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 13, 2024 |
ASXC / Asensus Surgical, Inc. / Beryl Capital Management LLC Passive Investment SC 13G/A 1 asxc13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Asensus Surgical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04367G103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-19437 Asensus Surgical, Inc. (Exact name of registrant as specified in i |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
Asensus Surgical, Inc. 1 TW Alexander Drive Suite 160 Durham, North Carolina 27703 Exhibit 99.3 Asensus Surgical, Inc. 1 TW Alexander Drive Suite 160 Durham, North Carolina 27703 TO: Cede & Co. Depository Trust Company 55 Water Street New York, New York 10041-0099 FROM Continental Stock Transfer & Trust Company, as Warrant Agent DATE: August 22, 2024 RE: Notice of Closing of Merger Transaction by Asensus Surgical, Inc. (ASXC) ***************************************************** |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASENSUS SURGICAL, INC. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASENSUS SURGICAL, INC. 1. The name of this corporation is: Asensus Surgical, Inc. (hereinafter, this “Corporation”). 2. The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle. The name of its registered agent at such address |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 22, 2024 |
Asensus Surgical, Inc. 1 TW Alexander Drive Suite 160 Durham, North Carolina 27703 Exhibit 99.2 Asensus Surgical, Inc. 1 TW Alexander Drive Suite 160 Durham, North Carolina 27703 TO: [Individual July 31, 2023 Warrant Holder] cc: Continental Stock Transfer & Trust Company, as Warrant Agent FROM Asensus Surgical, Inc. DATE: August 22 2024 RE: Notice of Closing of Merger Transaction **************************************************************************************************** |
|
| August 22, 2024 |
Exhibit 99.1 JOINT PRESS RELEASE: Asensus Surgical Announces Closing of Acquisition by KARL STORZ KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™ Research Triangle Park, N.C., (US) / Tuttlingen (Germany), August 22, 2024 - Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ASENSUS SURGICAL, INC., a Delaware corporation August 22, 2024 TABLE OF CONTENTS Page ARTICLE I Offices Section 1. Principal Executive Office 1 Section 2. Other Offices 1 ARTICLE II Meetings of Shareholders Section 1. Place and Conduct of Meetings 1 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice of Shareholders’ Meetin |
|
| August 22, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on September 03, 2024, pursuant to the provisions of Rule 12d2-2 (a). |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 22, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 20, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 13, 2024 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024 RESEARCH TRIANGLE PARK, N.C.- August 13, 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights ● Announced a definit |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 13, 2024 |
Asensus Surgical 2Q24 Earnings Prepared Remarks Exhibit 99.2 Asensus Surgical 2Q24 Earnings Prepared Remarks Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical second quarter financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. In addition to the financial updates, we are also going to pr |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SURGICAL, INC. ( |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 15, 2024 |
ASXC / Asensus Surgical, Inc. / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Asensus Surgical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04367G103 (CUSIP Number) July 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| July 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| June 24, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Asensus Surgical, Inc. |
|
| June 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| June 7, 2024 |
Press Release issued June 7, 2024 by Asensus Surgical, Inc. Exhibit 99.1 Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C. – June 7, 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital sol |
|
| June 7, 2024 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| June 7, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and among KARL STORZ ENDOSCOPY-AMERICA, INC., Karl Storz California Inc. and Asensus Surgical, Inc., Dated as of June 6, 2024 Table of Contents Page Number SECTION 1 - THE MERGER 1 1.1. The Merger 1 1.2. Effective Time 2 1.3. The Closing 2 1.4. Directors and Officers of the Surviving Corporation 2 1.5. Subsequent Actions 3 SECTION 2 - CONVERSION OF SECUR |
|
| June 7, 2024 |
Exhibit 99.1 Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C. – June 7, 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital sol |
|
| June 7, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and among KARL STORZ ENDOSCOPY-AMERICA, INC., Karl Storz California Inc. and Asensus Surgical, Inc., Dated as of June 6, 2024 Table of Contents Page Number SECTION 1 - THE MERGER 1 1.1. The Merger 1 1.2. Effective Time 2 1.3. The Closing 2 1.4. Directors and Officers of the Surviving Corporation 2 1.5. Subsequent Actions 3 SECTION 2 - CONVERSION OF SECUR |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 15, 2024 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024 RESEARCH TRIANGLE PARK, N.C.- May 14, 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the first quarter 2024. Recent Highlights ● Announced non-binding ac |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 15, 2024 |
ASXC First Quarter 2024 Earnings Call Transcript May 14, 2024 Exhibit 99.2 ASXC First Quarter 2024 Earnings Call Transcript May 14, 2024 Forward Looking Statements - Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical first quarter business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. Before |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENS |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 -12-31FY2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2024 |
Exhibit 10.1 SECURED PROMISSORY NOTE April 3, 2024 For value received, Asensus Surgical, Inc., a Delaware corporation (herein called the “Maker”), hereby promises to pay to KARL STORZ SE & Co. KG, a Kommanditgesellschaft organized under the laws of Germany, or its permitted assigns (hereinafter referred to as the “Holder”), the principal sum of up to $20,000,000 or so much thereof as remains outst |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 3, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| April 3, 2024 |
Exhibit 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Agreement”) is entered into as of April 3, 2024, by and among Asensus Surgical, Inc., a Delaware corporation, formerly known as TransEnterix, Inc. (“Asensus”), Asensus Surgical US, Inc., a Delaware corporation, formerly known as TransEnterix Surgical, Inc. (“Asensus US”), Asensus Surgical Eur |
|
| April 3, 2024 |
Exhibit 99.1 Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG KARL STORZ to provide up to $20 million in bridge financing RESEARCH TRIANGLE PARK, N.C.—April 3rd , 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 25, 2024 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023 RESEARCH TRIANGLE PARK, N.C.- March 21, 2024 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and |
|
| March 25, 2024 |
ASXC Fourth Quarter 2023 Earnings Call Transcript Exhibit 99.2 ASXC Fourth Quarter 2023 Earnings Call Transcript Forward Looking Statements - Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical fourth quarter and full year 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer |
|
| March 21, 2024 |
Form of Employee Restricted Stock Unit/Performance Restricted Stock Unit Award Notice. Exhibit 10.3.2 ASENSUS SURGICAL, INC. [RESTRICTED STOCK UNITS] [PERFORMANCE RESTRICTED STOCK UNITS] AWARD NOTICE Asensus Surgical, Inc., a Delaware corporation (the “Company”), has granted [performance-based] restricted stock units award [the “RSUs”)][(the “PRSUs”)] to acquire shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) to the individual named below. |
|
| March 21, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries (As of March 15, 2024) Name of Subsidiary Jurisdiction of Incorporation Asensus Surgical US, Inc. Delaware Asensus International, Inc. Delaware Asensus Surgical Italia, S.r.l. Italy Asensus Surgical Europe S.à r.l. Luxembourg Asensus Surgical Netherlands B.V. Netherlands Asensus Surgical Israel Ltd Israel Asensus Surgical Canada, Inc. Ontario, Canada Asensus Surgical Japa |
|
| March 21, 2024 |
Compensation Recoupment Policy of Asensus Surgical, Inc., effective October 2, 2023. Exhibit 97 Asensus Surgical, Inc. Compensation Recoupment Policy Approved – November 30, 2023, Effective October 2, 2023 1. INTRODUCTION The Board of Directors (the “Board”) of Asensus Surgical, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Compensation Recoupment Policy (this “Policy”) providing for |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SU |
|
| January 8, 2024 |
Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update Exhibit 99.1 Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-Jan 8, 2024- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update. 2023 Full Year Highlights ● Over 3,550 procedures were performed gl |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 4, 2024 |
Exhibit 99.1 Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System Surgeons Applaud LUNA's Innovative Capabilities RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-January 4, 2024 - Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced a key development milestone for LUNA™, the C |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| November 16, 2023 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023 RESEARCH TRIANGLE PARK, N.C.- Nov. 14, 2023 -(GLOBE NEWSWIRE) Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financia |
|
| November 16, 2023 |
ASXC Third Quarter 2023 Earnings Call Transcript Exhibit 99.2 ASXC Third Quarter 2023 Earnings Call Transcript Forward Looking Statements - Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical third quarter 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. Before we begi |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 A |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 19, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 11, 2023 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2023 RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)—August 10, 2023- Asensus Surgical, Inc. (“the Company”) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its oper |
|
| August 11, 2023 |
ASXC Second Quarter 2023 Earnings Call Transcript Exhibit 99.2 ASXC Second Quarter 2023 Earnings Call Transcript Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical second quarter 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. Before we begin, I would like to caution |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSU |
|
| July 28, 2023 |
Asensus Surgical Announces $10 Million Registered Direct Offering EXHIBIT 99.1 Asensus Surgical Announces $10 Million Registered Direct Offering RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)—July 27, 2023—Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that it has entered into |
|
| July 28, 2023 |
EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT ASENSUS SURGICAL, INC. Warrant Shares: Initial Exercise Date: July 31, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initia |
|
| July 28, 2023 |
Table of Contents PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated April 28, 2022) Registration Number 333-263711 23,809,524 Shares of Common Stock Common Warrants to Purchase up to 23,809,524 Shares of Common Stock Up to 23,809,524 Shares of Common Stock Underlying the Common Warrants We are offering 23,809,524 shares of our common stock, par value $0. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| July 28, 2023 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 27, 2023, between Asensus Surgical, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| June 8, 2023 |
Filing Fee Table (filed herewith) Exhibit 107.1 Calculation of Filing Fee Table Form S-3 ASR (Form Type) Asensus Surgical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| June 6, 2023 |
Exhibit 10.1 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN Amended and Restated as of: June 6, 2023 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN 1. Purpose 1 2. Definitions 1 3. Administration of the Plan 5 4. Shares Subject to Plan 6 5. Limitation on Awards to Non-Employee Directors 6 6. Specific Terms of Awards 7 7. Certain Provisions Applicab |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| June 5, 2023 |
Corporate Presentation of Asensus Surgical, Inc. June 5, 2023 Exhibit 99.1 |
|
| May 15, 2023 |
ASXC First Quarter 2023 Earnings Call Transcript Exhibit 99.2 ASXC First Quarter 2023 Earnings Call Transcript Forward Looking Statements - Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical first quarter 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Chief Financial Officer. Before we begi |
|
| May 15, 2023 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2023 RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)—May 11, 2023- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 11, 2023 |
Form of 2023 Performance-Based Restricted Stock Unit Award Notice Exhibit 10.1 ASENSUS SURGICAL, INC. PERFORMANCE RESTRICTED STOCK UNITS AWARD NOTICE Asensus Surgical, Inc., a Delaware corporation (the “Company”), has granted performance-based restricted stock units award (the “PRSUs”) to acquire shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) to the individual named below. The terms and conditions of the PRSUs are set |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENS |
|
| April 27, 2023 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| April 27, 2023 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 2, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SU |
|
| March 2, 2023 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2022 RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)—March 2, 2023- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ (PGS), today announced its op |
|
| March 2, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries (As of February 24, 2023) Name of Subsidiary Jurisdiction of Incorporation Asensus Surgical US, Inc. Delaware Asensus International, Inc. Delaware Asensus Surgical Italia, S.r.l. Italy Asensus Surgical Europe S.à r.l. Luxembourg Asensus Surgical Netherlands B.V. Netherlands Asensus Surgical Israel Ltd Israel Asensus Surgical Canada, Inc. Ontario, Canada Asensus Surgical J |
|
| February 21, 2023 |
Corporate Presentation of Asensus Surgical, Inc. February 21, 2023 Exhibit 99.1 |
|
| February 21, 2023 |
Asensus Surgical Provides Corporate Update Exhibit 99.2 Asensus Surgical Provides Corporate Update RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-February 21, 2023- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, is providing this corporate update in conjunction with its previously announced Invest |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2023 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 12, 2023 |
Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update Exhibit 99.1 Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-Jan. 9, 2023- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update. Four |
|
| November 14, 2022 |
ASXC Third Quarter 2022 Earnings Call Transcript Exhibit 99.2 ASXC Third Quarter 2022 Earnings Call Transcript Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical third quarter 2022 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. Before we begin, I would like to caution li |
|
| November 14, 2022 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2022 RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-November 10, 2022- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and finan |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 A |
|
| August 11, 2022 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2022 RESEARCH TRIANGLE PARK, N.C.-(GLOBE NEWSWIRE)-August 8, 2022- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and financi |
|
| August 11, 2022 |
Asensus Surgical, Inc. Q2 2022 Earning Call Transcript Exhibit 99.2 Asensus Surgical, Inc. Q2 2022 Earning Call Transcript Corporate Participants: Mark Klausner, Westwicke Partners Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Presentation: Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical second quarter 2022 business and financial update conference call. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSU |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 10, 2022 |
Asensus Surgical, Inc. Up to $100 Million Common Stock 424B5 1 transe20220509424b5.htm FORM 424B5 PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated April 28, 2022) Registration Number 333-263711 Asensus Surgical, Inc. Up to $100 Million Common Stock We are offering, through this prospectus supplement and the accompanying prospectus, up to $100 million of shares of our common stock, $0.001 par value per share in this offering |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 5, 2022 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2022 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-May 4, 2022- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and financial re |
|
| May 5, 2022 |
Asensus Surgical, Inc. Q1 2022 Earning Call Transcript Exhibit 99.2 Asensus Surgical, Inc. Q1 2022 Earning Call Transcript Corporate Participants: Mark Klausner, Westwicke Partners Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Presentation: Mark Klausner Good afternoon, everyone, and thank you for joining us for the Asensus Surgical first quarter 2022 business and financial update conference call. O |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENS |
|
| April 26, 2022 |
Asensus Surgical, Inc. 1 TW Alexander Drive, Suite 160 Durham, North Carolina 27703 April 26, 2022 Asensus Surgical, Inc. 1 TW Alexander Drive, Suite 160 Durham, North Carolina 27703 April 26, 2022 Via EDGAR and Electronic Mail Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Asensus Surgical, Inc. Registration Statement on Form S-3 (File No. 333-263711) Ladies and Gentlemen: We respectfully request that th |
|
| April 25, 2022 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| April 25, 2022 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 transe20220420def14a.htm FORM DEF 14A Table of Contents Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive A |
|
| March 18, 2022 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Asensus Surgical, Inc. |
|
| March 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 18, 2022 |
Exhibit 1.2 Execution Version AMENDMENT NO. 1 TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT March 18, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Oppenheimer & Co. Inc. 85 Broad Street, 23rd Floor New York, NY 10004 Ladies and Gentlemen: Asensus Surgical, Inc. (the ?Company?), Cantor Fitzgerald & Co. (?Cantor?), Robert W. Baird & Co. Incorporated (?Baird?) and Oppenheimer & C |
|
| March 18, 2022 |
As Filed with the Securities and Exchange Commission on March 18, 2022 Table of Contents As Filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 2, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 2, 2022 |
Exhibit 99.2 C O R P O R A T E P A R T I C I P A N T S Mark Klausner, Westwicke Partners Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Swayampakula Ramakanth, H.C. Wainwright & Co. Ross Osborn, Cantor Fitzgerald & Co. P R E S E N T A T I O N Operator Welcome to the Asensus Surgical, Inc. Fourth |
|
| March 2, 2022 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-February 28, 2022- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its opera |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SU |
|
| February 28, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries (As of February 21, 2022) Name of Subsidiary Jurisdiction of Incorporation Asensus Surgical US, Inc. Delaware Asensus International, Inc. Delaware Asensus Surgical Italia, S.r.l. Italy Asensus Surgical Europe S.?.r.l Luxembourg Asensus Surgical Netherlands B.V. Netherlands Asensus Surgical Israel Ltd Israel Asensus Surgical Canada, Inc. Ontario, Canada Asensus Surgical Ja |
|
| February 28, 2022 |
EXHIBIT 10.6.1 PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED, AS INDICATED WITH ?*? AND BRACKETS, BECAUSE THE INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. AMENDMENT TO LICENCE CONTRACT [************************] This Amendment to Licence Contract (the ?Amendment?) amends, effective as of July 2, 2021 (the ?Amended Date?), the Licence Contract Between the |
|
| February 28, 2022 |
Form of Employee Restricted Stock Unit/Performance Restricted Stock Unit Award Notice Exhibit 10.4.2 ASENSUS SURGICAL, INC. RESTRICTED STOCK UNITS AWARD NOTICE Asensus Surgical, Inc., a Delaware corporation (the ?Company?), has granted restricted stock units award (the ?RSUs?) to acquire shares (the ?Shares?) of its common stock, par value $0.001 per share (the ?Common Stock?) to the individual named below. The terms and conditions of the RSUs are set forth in this award cover shee |
|
| February 28, 2022 |
Exhibit 10.4.1 ASENSUS SURGICAL, INC. STOCK OPTION AWARD NOTICE Asensus Surgical, Inc., a Delaware corporation (the ?Company?), has granted an option (the ?Option?) to purchase shares (the ?Shares?) of its common stock, par value $0.001 per share (the ?Common Stock?) to the individual named below. The terms and conditions of the Option are set forth in this award cover sheet and in the attachment |
|
| February 28, 2022 |
EXHIBIT 10.5 ASENSUS SURGICAL, INC. EXECUTIVE DEFERRED COMPENSATION PLAN ARTICLE I. INTRODUCTION. WHEREAS, Asensus Surgical, Inc. (the ?Company?) wishes to establish a plan solely to provide deferred compensation for a select group of management or highly compensated employees within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of the Employee Retirement Income Security Act of 1974 (?ER |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 13, 2022 |
Corporate Presentation of Asensus Surgical, Inc. January 2022 Exhibit 99.1 |
|
| January 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| January 10, 2022 |
Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update Exhibit 99.1 Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-Jan. 10, 2022- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today provided a preliminary 2021 year-end corporate update. Four |
|
| November 4, 2021 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2021 November 3, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and financi |
|
| November 4, 2021 |
Exhibit 99.2 Company: Asensus Surgical, Inc. Conference Title: Q3 2021 Asensus Surgical, Inc. Earnings Call Moderator: Mark Klausner, Westwicke Partners, Investor Relations Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Date: November 3, 2021 P R E S E N T A T I O N Operator Welcome to the Asensus Third Quarter Financial and Operating Results Con |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 A |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 27, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| October 4, 2021 |
Asensus Surgical Announces Board Chair Transition Exhibit 99.1 Asensus Surgical Announces Board Chair Transition RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Oct. 4, 2021- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced that Paul LaViolette, who has served as the Company?s Board Chair si |
|
| September 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| September 27, 2021 |
Exhibit 99.1 Asensus Surgical Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center Loginov Moscow is the first Russian hospital to initiate a Senhance Surgical System program RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Sept. 27, 2021- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon a |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| September 1, 2021 |
Exhibit 99.1 Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities Additional Intelligent Surgical Unit? (ISU?) features will further extend augmented intelligence leadership in surgery Image Caption: The Senhance Surgical System pictured with the latest ISU model that includes expanded augmented intelligence features such as 3D measurement and enhanced camera |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| August 6, 2021 |
Exhibit 99.2 Company: Asensus Surgical, Inc. Conference Title: Q2 2021 Asensus Surgical, Inc. Earnings Call Moderator: Mark Klausner, Westwicke Partners, Investor Relations Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Date: August 6, 2021 P R E S E N T A T I O N Operator: Good afternoon, ladies and gentlemen, and welcome to the Asensus Surgical |
|
| August 6, 2021 |
EXHIBIT 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2021 August 5, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and financia |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SURGICAL, INC. ( |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021 As filed with the Securities and Exchange Commission on July 26, 2021 Registration No. |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| July 23, 2021 |
Exhibit 10.1 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN Amended and Restated as of: July 22, 2021 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN 1. Purpose 1 2. Definitions 1 3. Administration of the Plan 5 4. Shares Subject to Plan 6 5. Limitation on Awards to Non-Employee Directors 6 6. Specific Terms of Awards 7 7. Certain Provisions Applica |
|
| July 15, 2021 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| July 15, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| July 15, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ASENSUS SURGICAL, INC. (a Delaware corporation) The following are the Bylaws (?Bylaws?) of ASENSUS SURGICAL, INC., a Delaware corporation (the ?Corporation?), effective as of July 15, 2021. ARTICLE I OFFICES Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at 1 TW Alexander Drive, Suite 160, Durha |
|
| June 29, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| June 22, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| June 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| June 3, 2021 |
ASENSUS SURGICAL 2021 ANNUAL MEETING OF STOCKHOLDERS IS ADJOURNED Exhibit 99.1 ASENSUS SURGICAL 2021 ANNUAL MEETING OF STOCKHOLDERS IS ADJOURNED June 3, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- June 3, 2021- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery?, today announced that the Company?s 2021 Annual Meeting of S |
|
| June 3, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| May 19, 2021 |
CALCULATION OF REGISTRATION FEE Table of Contents Filed pursuant to Rule 424(b)(5) Registration Number: 333-256284 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0. |
|
| May 19, 2021 |
EX-1.1 2 ex251690.htm EXHIBIT 1.1 Exhibit 1.1 ASENSUS SURGICAL, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 19, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Robert W. Baird & Co. Incorporated 777 E. Wisconsin Avenue Milwaukee, Wisconsin 53202 Oppenheimer & Co. Inc. 85 Broad Street, 23rd Floor New York, NY 10004 Ladies |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 19, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 19, 2021 Registration No. |
|
| May 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 19, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| May 13, 2021 |
EX-99.2 3 ex249929.htm EXHIBIT 99.2 Exhibit 99.2 Company: Asensus Surgical, Inc. Conference Title: Q1 2021 Asensus Surgical, Inc. Earnings Call Moderator: Mark Klausner, Westwicke Partners, Investor Relations Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Date: May 11, 2021 P R E S E N T A T I O N Operator Good afternoon, ladies and gentlemen, an |
|
| May 13, 2021 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2021 May 11, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery?, today announced its operating and financial r |
|
| May 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENS |
|
| April 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| April 30, 2021 |
Exhibit 10.1 Non-Employee Director Compensation Program Effective July 1, 2021, the Asensus Surgical, Inc. Non-Employee Director Compensation Program is: Annual Cash Retainer (1) Annual Equity Award (2) Initial Equity Award (2) Non-Employee Director role: Dollar value Election to be paid in equity Equity grant of stock options or restricted stock units with a value of $45,000. Director can elect t |
|
| April 28, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| April 22, 2021 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| April 22, 2021 |
Table of Contents Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12 ASENSUS SURGICAL, INC. |
|
| March 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| March 12, 2021 |
Exhibit 99.2 Company: Asensus Surgical, Inc. Conference Title: Q4 2020 Asensus Surgical, Inc. Earnings Call Moderator: Mark Klausner, Westwicke Partners, Investor Relations Anthony Fernando, President and Chief Executive Officer Shameze Rampertab, Chief Financial Officer Date: March 11, 2021 P R E S E N T A T I O N Operator Good afternoon, ladies and gentlemen, and welcome to the Asensus Surgical |
|
| March 12, 2021 |
Exhibit 99.1 Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2020 March 11, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operatin |
|
| March 11, 2021 |
Exhibit 10.4.8 ASENSUS SURGICAL, INC. NON-QUALIFIED STOCK OPTION AGREEMENT ? QUARTERLY GRANT IN LIEU OF CASH RETAINER (NON-EMPLOYEE DIRECTOR) 1. Grant of Option. ASENSUS SURGICAL, INC. (the ?Company?) hereby grants, as of (the ?Date of Grant?), to (the ?Optionee?) an option (the ?Option?) to purchase up to shares of the Company?s common stock, par value $0.001 per share (the ?Shares?), at an exerc |
|
| March 11, 2021 |
Exhibit 4.1 |
|
| March 11, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries (As of March 8, 2021) Name of Subsidiary Jurisdiction of Incorporation Asensus Surgical US, Inc. Asensus International, Inc. SafeStitch, LLC Asensus Surgical Italia, S.r.l. Asensus Surgical Europe, Sarl Asensus Surgical Netherlands B.V. Asensus Surgical Israel LTD Asensus Surgical Canada, Inc. TransEnterix Japan K.K. TransEnterix Taiwan Ltd. Delaware Delaware Virginia Ita |
|
| March 11, 2021 |
EX-10.47 11 ex232213.htm EXHIBIT 10.4.7 Exhibit 10.4.7 ASENSUS SURGICAL, INC. STOCK AWARD CERTIFICATE Date of Issuance: [] Issuer: Asensus Surgical, Inc., a Delaware corporation Awardee: Plan: Shares are issued under the Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan of the Company (the “Plan”) Number of Shares: Reason for Issuance: Payment of quarterly stock in lieu of ca |
|
| March 11, 2021 |
Exhibit 10.4.5 ASENSUS SURGICAL, INC. NON-QUALIFIED STOCK OPTION AGREEMENT ? ANNUAL GRANT (NON-EMPLOYEE DIRECTOR) 1. Grant of Option. ASENSUS SURGICAL, INC. (the "Company") hereby grants, as of (the "Date of Grant"), to (the "Optionee") an option (the "Option") to purchase up to shares of the Company's common stock, par value $0.001 per share (the "Shares"), at an exercise price per share equal to |
|
| March 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 ASENSUS SU |
|
| March 11, 2021 |
Appendix C to the Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan. EX-10.41 5 ex232207.htm EXHIBIT 10.4.1 Exhibit 10.4.1 APPENDIX C TO ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN FOR CANADIAN RESIDENT EMPLOYEES This Appendix C to the Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan (the “Plan”) for Canadian Resident Employees (this “Appendix”) sets forth the modifications to Plan terms and procedures established |
|
| March 11, 2021 |
EX-10.46 10 ex232212.htm EXHIBIT 10.4.6 Exhibit 10.4.6 ASENSUS SURGICAL, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT NON-EMPLOYEE DIRECTOR This RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of [ ] (the “Date of Grant”), is made by Asensus Surgical, Inc., a Delaware corporation (the “Company”), to [ ] (the “Participant”). RECITALS The Amended and Restated Incentive Compensation P |
|
| March 11, 2021 |
Form of Employee Restricted Stock Unit Agreement pursuant to the Plan. Exhibit 10.4.3 ASENSUS SURGICAL, INC. FORM OF ANNUAL RESTRICTED STOCK UNIT AWARD AGREEMENT U.S. EMPLOYEES This ANNUAL RESTRICTED STOCK UNIT AWARD AGREEMENT (this ?Agreement?) dated as of [ ] (the ?Date of Grant?), is made by Asensus Surgical, Inc., a Delaware corporation (the ?Company?), to [ ] (the ?Participant?). RECITALS The Amended and Restated Incentive Compensation Plan of the Company (the ? |
|
| March 11, 2021 |
EX-10.4 4 ex232206.htm EXHIBIT 10.4 Exhibit 10.4 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN Amended and Restated as of: June 8, 2020 ASENSUS SURGICAL, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION PLAN 1. Purpose 2. Definitions 3. Administration of the Plan 5 4. Shares Subject to Plan 6 5. Limitation on Awards to Non-Employee Directors 6 6. Specific Terms of Awards |
|
| March 11, 2021 |
Asensus Surgical, Inc. Non-Employee Director Compensation Program, effective July 1, 2020 Exhibit 10.8 Non-Employee Director Compensation Program Effective July 1, 2020, the Asensus Surgical, Inc. Non-Employee Director Compensation Program is: Annual Equity Retainer(1) Annual Equity Award (2) Initial Equity Award (2) Non-Employee Director role: Dollar value Paid in equity in lieu of cash (2) Equity grant of stock options or restricted Equity grant of stock options or restricted Baselin |
|
| March 11, 2021 |
Form of Employee Performance-Based Restricted Stock Unit Agreement pursuant to the Plan. EX-10.44 8 ex232210.htm EXHIBIT 10.4.4 Exhibit 10.4.4 ASENSUS SURGICAL, INC. FORM OF ANNUAL PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This ANNUAL PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of [] (the “Date of Grant”), is made by Asensus Surgical, Inc., a Delaware corporation (the “Company”), to [ ] (the “Participant”). RECITALS The Amended and |
|
| March 11, 2021 |
Form of Employee Stock Option Agreement pursuant to the Plan. Exhibit 10.4.2 ASENSUS SURGICAL, INC. FORM OF STOCK OPTION AGREEMENT (U.S. EMPLOYEES) 1. Grant of Option. ASENSUS SURGICAL, INC. (the ?Company?) hereby grants, as of [] (the ?Date of Grant?), to[] (the ?Optionee?) an option (the ?Option?) to purchase up to [] shares of the Company?s common stock, par value $0.001 per share (the ?Shares?), at an exercise price per share equal to $0.41 (the ?Exercis |
|
| March 11, 2021 |
EX-4.8 3 ex232205.htm EXHIBIT 4.8 Exhibit 4.8 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Asensus Surgical, Inc. (“us,” “our,” “we,” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is a su |
|
| March 3, 2021 |
Exhibit 99.1 Asensus Surgical Announces FDA Clearance in General Surgery Indications Expand to Include New Procedures in Large General Surgery Market RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- March 3, 2021- Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era o |
|
| March 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| February 25, 2021 |
EX-3.2 3 ex229523.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ASENSUS SURGICAL, INC. (a Delaware corporation) The following are the Bylaws (“Bylaws”) of ASENSUS SURGICAL, INC., a Delaware corporation (the “Corporation”), effective as of February 23, 2021. Article I OFFICES Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2021 Date of Report (date of earliest event reported) Asensus Surgical, Inc. |
|
| February 25, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TRANSENTERIX, INC. TransEnterix, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is TransEnterix, Inc. The Corporation was originally incorporated under the name ?NCS Ventures Corp?. The Corporation?s original Certificate of Incorpo |
|
| February 23, 2021 |
EX-99.2 3 ex228359.htm EXHIBIT 99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery New name reflects commitment to pioneering a new era of Performance-Guided Surgery to help improve surgical results and patient outcomes RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-February 23, 2021- Tran |
|
| February 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| February 23, 2021 |
Investor Day Presentation, dated February 23, 2021 EX-99.1 2 ex228273.htm EXHIBIT 99.1 Exhibit 99.1 |
|
| February 16, 2021 |
CUSIP No: 89366M300 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* TransEnterix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89366M300 (CUSIP Number) D |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 8, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 26, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| January 28, 2021 |
TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million EX-99.2 5 ex222858.htm EXHIBIT 99.2 EXHIBIT 99.2 TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million RESEARCH TRIANGLE PARK, N.C. — (BUSINESS WIRE)—Jan. 26, 2021— TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally |
|
| January 28, 2021 |
EX-1.1 2 ex222856.htm EXHIBIT 1.1 EXHIBIT 1.1 23,083,333 SHARES of Common Stock TransEnterix, Inc. AMENDED AND RESTATED UNDERWRITING AGREEMENT January 26, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: The undersigned, TransEnterix, Inc., a |
|
| January 28, 2021 |
23,083,333 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration Number: 333-236200 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2020) 23,083,333 Shares Common Stock We are offering 23,083,333 shares of our common stock, $0. |
|
| January 28, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TransEnterix, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89366M300 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 28, 2021 |
TransEnterix Announces $25 Million Bought Deal Offering of Common Stock EX-99.1 4 ex222857.htm EXHIBIT 99.1 EXHIBIT 99.1 TransEnterix Announces $25 Million Bought Deal Offering of Common Stock RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)—Jan. 26, 2021- TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today anno |
|
| January 27, 2021 |
TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million FWP 1 transe20210126bfwp.htm FORM FWP Free Writing Prospectus dated January 26, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated January 26, 2021 Registration Statements Nos. 333-236200 and 333-252451 TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million RESEARCH TRIANGLE PARK, N.C. — (BUSINESS WIRE)—Jan. 26, 2021— |
|
| January 27, 2021 |
TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million Free Writing Prospectus dated January 26, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated January 26, 2021 Registration Statements Nos. |
|
| January 26, 2021 |
TransEnterix Announces $25 Million Bought Deal Offering of Common Stock FWP 1 transe20210126fwp.htm FORM FWP Free Writing Prospectus dated January 26, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated January 26, 2021 Registration Statement No. 333-236200 TransEnterix Announces $25 Million Bought Deal Offering of Common Stock RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)—Jan. 26, 2021- TransEnterix, Inc. (NYSE American: TRXC) (“Tra |
|
| January 26, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 26, 2021 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 26, 2021 |
S-3MEF 1 transe20210125s3mef.htm FORM S-3MEF As filed with the Securities and Exchange Commission on January 26, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSENTERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 11-2962080 (State or Other Jurisdiction |
|
| January 19, 2021 |
Exhibit 99.1 TransEnterix Receives CE Mark for Machine Vision System in Robotic Surgery The Intelligent Surgical Unit™ Enables Augmented Intelligence on the SenhanceⓇ Surgical System RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- January 19, 2021- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimal |
|
| January 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 19, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| January 14, 2021 |
TransEnterix Announces $31.25 Million Registered Direct Offering of Common Stock EX-99.1 5 ex220751.htm EXHIBIT 99.1 Exhibit 99.1 TransEnterix Announces $31.25 Million Registered Direct Offering of Common Stock RESEARCH TRIANGLE PARK, N.C.- (BUSINESS WIRE)-Jan. 12, 2021- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered |
|
| January 14, 2021 |
TransEnterix, Inc. 25,000,000 Shares Common Stock 424B5 1 transe20210113424b5.htm FORM 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Number: 333-236200 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2020) TransEnterix, Inc. 25,000,000 Shares Common Stock We are offering to certain institutional and accredited investors 25,000,000 shares of our common stock, $0.001 par value per share, in this offering at a purchas |
|
| January 14, 2021 |
EX-10.1 3 ex220749.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2021, between TransEnterix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, su |
|
| January 14, 2021 |
EX-10.2 4 ex220750.htm EXHIBIT 10.2 Exhibit 10.2 Execution Version January 11, 2021 STRICTLY CONFIDENTIAL TransEnterix, Inc. 635 Davis Drive, Suite 300 Morrisville, North Carolina 27560 Attn: Anthony Fernando, President and Chief Executive Officer Dear Mr. Fernando: This letter agreement (this “Agreement”) constitutes the agreement between TransEnterix, Inc. (the “Company”) and H.C. Wainwright & C |
|
| January 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| January 6, 2021 |
TransEnterix Provides Preliminary 2020 Year-End Corporate Update EX-99.1 2 ex219892.htm EXHIBIT 99.1 Exhibit 99.1 TransEnterix Provides Preliminary 2020 Year-End Corporate Update January 6, 2021 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-Jan. 6, 2021- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today provided a preliminary 2020 yea |
|
| January 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2021 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| December 17, 2020 |
Exhibit 99.1 TransEnterix Announces Southern Surgical Hospital to Initiate a Senhance® Digital Laparoscopic Program Represents the Third Senhance Surgical Program Initiated in Louisiana RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-December 17, 2020- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve mini |
|
| December 17, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2020 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| December 16, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 16, 2020 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| December 16, 2020 |
Exhibit 99.1 TransEnterix Announces Approval of Senhance® Surgical System in Russian Federation Approval allows for marketing and sale of Senhance Surgical System for digital laparoscopy RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-December 16, 2020- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve min |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2020 Date of Report (date of earliest event reported) TransEnterix, Inc. |
|
| November 9, 2020 |
Exhibit 99.1 TransEnterix, Inc. Reports Operating and Financial Results for the Third Quarter 2020 November 5, 2020 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- November 5, 2020 - TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial |
|
| November 9, 2020 |
Exhibit 99.2 Company: TRANSENTERIX, INC. Conference Title: Q3 2020 TransEnterix, Inc. Earnings Call Moderator: Mark Klausner Date: November 5, 2020 PRESENTATION Operator Good afternoon, ladies and gentlemen, and welcome to the TransEnterix Third Quarter Business Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session an |
|
| November 6, 2020 |
Exhibit 10.1.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment, dated as of September 16, 2020 (“Amendment”), is an amendment to the Employment Agreement, dated August 14, 2020 (the “Agreement”), between TransEnterix Canada, Inc., an Ontario corporation (“TransEnterix”) and Shameze Rampertab, an individual (the “Executive”). Defined terms used in this Amendment without definition have the meaning |
|
| November 6, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19437 T |
|
| November 5, 2020 |
Exhibit 10.2 TRANSENTERIX, INC. EMPLOYMENT INDUCEMENT PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT This EMPLOYMENT INDUCEMENT PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of August 24, 2020 (the “Date of Grant”), is made by TransEnterix, Inc., a Delaware corporation (the “Company”), to Shameze Rampertab (the “Participant”). RECITALS This Award is an employment |
|
| November 5, 2020 |
Exhibit 10.4 TRANSENTERIX, INC. EMPLOYMENT INDUCEMENT STOCK OPTION AWARD AGREEMENT 1. Grant of Option. TRANSENTERIX, INC. (the “Company”) hereby grants, as of August 24, 2020 (the “Date of Grant”), to Shameze Rampertab (the “Optionee”) a non-qualified stock option (the “Option”) to purchase up to 150,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), at an exercis |
|
| November 5, 2020 |
Exhibit 10.3 TRANSENTERIX, INC. EMPLOYMENT INDUCEMENT RESTRICTED STOCK UNIT AWARD AGREEMENT This EMPLOYMENT INDUCEMENT RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of August 24, 2020 (the “Date of Grant”), is made by TransEnterix, Inc., a Delaware corporation (the “Company”), to Shameze Rampertab (the “Participant”). RECITALS This Award is an employment inducement award exempt |
|
| October 9, 2020 |
TransEnterix, Inc. Up to $40 Million of Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration Number: 333-236200 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2020) TransEnterix, Inc. |
|
| October 9, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 9, 2020 Date of Report (date of earliest event reported) TransEnterix, Inc. |
